Breast Cancer
Commentary
The New Cancer Stats Might Look Like a Death Sentence. They Aren’t.
Data show that people under 50 are experiencing higher rates of cancer than any generation before them.
Feature
How to Treat Cancer While Preserving Fertility
Some chemotherapies are known for their effects on oocytes, follicle maturation, and spermatogenesis, but knowledge about newer treatment options...
Latest News
ACS: Breast Cancer Incidence Rising, Mortality Disparities Persist
Deaths from breast cancer, however, declined from 1989 to 2022, with an overall drop of 44%.
Feature
The Biology of ‘Precancer’: Stopping Cancer Before It Starts
Why are some breast cancer types more likely to recur than others?
Feature
‘Cancer Doesn’t Wait’: How Prior Authorization Harms Care
Despite the large tumor, nestled in a sensitive area, a Boston-based radiation oncologist could envision a bright future for her patient.
Feature
Popular Weight Loss Drugs Now for Patients With Cancer?
Research suggests that obesity can reduce the effectiveness of cancer therapies.
From the Journals
Does Medicare Advantage Offer Higher-Value Chemotherapy?
Researchers conducted a cohort study to look at Medicare Advantage enrollment and treatment patterns for patients with cancer receiving...
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
Latest News
Screening Identifies Familial Risk for Hereditary Breast and Ovarian Cancer in Large Health System
The number needed to test to detect one BRCA1/2-positive patient decreased from 128 to 53 for women and from 119 to 42 for men when prescreening...
From the Journals
Black Women Have a Higher Risk for Death in BC Subtypes
Researchers examined racial differences in BC survival by subtype through conducting a systematic review and meta-analysis of 18 US studies.
News from the FDA/CDC
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The FDA also approved ribociclib and the aromatase inhibitor letrozole packaged together for the same indication.